Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial-Reference-Cited by-同舟云学术

Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Published:2021-11 Issue:11 Volume:9 Page:755-766
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Jongs Niels,Greene Tom,Chertow Glenn M,McMurray John J V,Langkilde Anna Maria,Correa-Rotter Ricardo,Rossing Peter,Sjöström C David,Stefansson Bergur V,Toto Robert D,Wheeler David C,Heerspink Hiddo J L

Funder

AstraZeneca PLC

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference29 articles.

1. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis;Fox;Lancet,2012

2. Microalbuminuria: target for renoprotective therapy PRO;Roscioni;Kidney Int,2014

3. The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients;Petrykiv;Diabetes Obes Metab,2017

4. The effect of liraglutide on renal function: a randomized clinical trial;von Scholten;Diabetes Obes Metab,2017

5. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials;Heerspink;Lancet Diabetes Endocrinol,2019

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of dapagliflozin in children with kidney disease: real-world data;Pediatric Nephrology;2024-08-06

2. Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world;Frontiers in Pharmacology;2024-08-05

3. Mendelian randomization study of sodium–glucose cotransporter 2 inhibitors in cardiac and renal diseases;Journal of International Medical Research;2024-08

4. SGLT2 inhibitor Dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis;Biomedicine & Pharmacotherapy;2024-08

5. Guidelines for clinical evaluation of chronic kidney disease in early stages;Clinical and Experimental Nephrology;2024-07-06